Fresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in second-round financing led by venture capital groups Arix Bioscience and RTW In
After more than a decade of fraught clinical development it looks like the end of the line for Pfizer/Lilly painkiller tanezumab, which promised to be an alternative to addictive opioid pai